Breega vs redalpine

Cori Clinical Raises €3.8M to Accelerate Clinical Trials

London-based Cori Clinical, a startup providing an AI-powered intelligence layer for clinical trials, has raised €3.8 million in a Seed round led by Breega, with participation from Enzo, Heartfelt, Together Ventures, and Bynd. The company plans to use the funds to expand delivery capacity, grow its team, and deepen regulatory and clinical intelligence in its platform. Dr. Emma Ogburn joins as Chief Clinical Officer from Lindus Health. Founded in 2025 by Jorn Jansen Schoonhoven (CEO) and Patricio Fernández (CTO), Cori Clinical creates a 'living blueprint' for trials, integrating internal knowledge with external data from registries and regulatory bodies like FDA, MHRA, and EMA. The startup claims its approach could reduce average trial set-up costs by at least 33%. It already works with two of the top five global CROs and has customers like Erasmus MC.

• Cori Clinical raised €3.8 million in a Seed round led by Breega.
• Participants include Enzo, Heartfelt, Together Ventures, and Bynd.
• Dr. Emma Ogburn joins as Chief Clinical Officer from Lindus Health.

Swiss VC Redalpine Raises $250 Million for A.I., Robotics and Biotech

Zurich-based venture capital firm Redalpine has closed its eighth early-stage fund, Redalpine Capital VIII (RAC VIII), at $250 million (approximately €225 million), its largest early-stage fund to date. The fund was oversubscribed, attracting both returning and new investors, including Aviva Investors, Flexstone Partners, and German development bank KfW. RAC VIII is 25% larger than its predecessor, which closed at $200 million in 2024, and will invest in 15-20 European startups at seed to Series A stages, with ticket sizes ranging from $1-15 million. Focus areas include AI, robotics, and biotech, with an emphasis on AI for drug discovery. Initial investments include Enact Intelligence, Helical, and Arlequin AI. Redalpine now manages over $1.4 billion in assets and has backed companies such as Mistral, N26, and Proxima Fusion. Managing Partner Sebastian Becker highlighted AI's potential to empower European founders, signaling a return of confidence in the region's ecosystem.

• Redalpine closed its eighth early-stage fund, RAC VIII, at $250 million (≈ €225 million), its largest to date.
• The fund was oversubscribed and is 25% larger than its predecessor, which raised $200 million in 2024.
• RAC VIII will invest in 15-20 European startups at seed to Series A, with checks of $1-15 million, focusing on AI, robotics, and biotech.

Calliora raises $6M for AI hospital billing accuracy

Munich-based startup calliora has raised $6 million (approx. €5.1 million) in a pre-seed round led by Bertelsmann Healthcare Investments (BHI) and Swiss VC redalpine. The company's AI platform helps hospitals find billing errors before invoices are sent to health insurers. This comes as German hospitals face stricter audit quotas from 2027 under the GKV contribution rate stabilization law, where high error rates could lead to 100% of invoices being audited. The platform integrates with existing hospital systems, covering coding, case review, MD audit management, and controlling. According to calliora, the platform is already in regular operation in hospitals across five German states, reducing per-case workload by over half and closing more than 90% of identified gaps before billing. The funds will be used to grow the AI, engineering, and product teams. The startup was founded in 2023 by Frederik Träuble and Jonas Wildberger.

• calliora raised $6 million (€5.1 million) in a pre-seed round led by Bertelsmann Healthcare Investments and redalpine.
• The startup's AI platform detects billing errors in hospitals before invoices are sent to insurers.
• From 2027, German hospitals face higher audit quotas up to 100% under the GKV contribution rate stabilization law.

A market that punishes narrative and rewards fundamentals: our current market view

Redalpine published a new market view article on September 29, 2026, discussing the current market dynamics.